Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole

American Journal of Health-System Pharmacy

Volumn 56, Issue 23 SUPPL. 4, 1999, Pages

  Sharma, Virender K ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Clinical studies; Dosage forms; Drugs, clinical effectiveness; Gastrointestinal drugs; Lansoprazole; Omeprazole; Suspensions

Indexed keywords

LANSOPRAZOLE; MYLANTA; OMEPRAZOLE;

CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SCREENING; DRUG STABILITY; DUODENUM ULCER; HUMAN; LIQUID; POWDER; PRIORITY JOURNAL; STOMACH PH; SUSPENSION;

EID: 0033485715     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/56.suppl_4.s18     Document Type: Conference Paper

References (19)

1. Walmark B. Mechanism of action of omeprazole. Scand J Gastroenterol Suppl. 1986; 118:11-6.
2. Sachs G. Proton-pump inhibitors and acid-related disorders. Pharmacotherapy. 1997; 17:22-37.
3. Prevacid (lansoprazole) package insert. Deerfield, IL: TAP Pharmaceuticals, Inc.; 1998 Jun.
4. Prilosec (omeprazole) package insert. Wayne, PA: Astra Merck Inc.; 1997 Sep.
5. Ostro MJ, Russell JA, Soldin SJ et al. Control of gastric pH with cimetidine boluses versus primed infusions. Gastroenterology. 1985; 89:532-7.
6. 2 receptor antagonists: constant infusions. Clin Ther. 1986; 89(suppl A):24-33.
7. Ballesteros MA, Hogan DL, Koss MA et al. Bolus or intravenous infusion of ranitidine: effects on gastric pH and acid secretion; a comparison of relative cost and efficacy. Ann Intern Med. 1990; 112:334-9.
8. Sharma VK, Heinzelmann EJ, Steinberg EN et al. Nonencapsulated, intact omeprazole granules effectively suppress intragastric acidity when administered via a gastrostomy. Am J Gastroenterol. 1997; 92:848-51.
9. Sharma VK, Ugheoke EA, Vasudeva R et al. The pharmacodynamics of lansoprazole administered via gastrostomy as intact, non-encapsulated granules. Aliment Pharmacol Ther. 1998; 12:1171-4.
10. Sharma VK, Vasudeva R, Howden CW. A study of the effects of per-gastrostomy administration of an alkaline suspension of omeprazole on intragastric acidity. Aliment Pharmacol Ther. 1999; 13:1091-6.
11. Sharma VK, Vasudeva R, Howden CW. Simplified lansoprazole suspension - a liquid formulation of lansoprazole - effectively suppresses intragastric acidity when administered via a gastrostomy. Am J Gastroenterol. 1999; 94:1813-7.
12. Burget DW, Chiverton SG, Junt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcer? A model of the relationship between ulcer healing and acid suppression. Gastroenterology. 1990; 99:345-51.
13. Bell NJV, Howden CW, Burget D et al. Appropriate acid suppression for the management of gastro-esophageal reflux disease. Digestion. 1992; 51(suppl 1):59-67.
14. Hunt RH. The importance of pH control in the management of GERD. Arch Intern Med. 1999; 159:649-57.
15. Phillips JO, Metzler MH, Palmieri TL et al. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med. 1996; 24:1793-1800.
16. Phillips JO, Metzler MH, Olsen K. The stability of simplified lansoprazole suspension (SLS). Gastroenterology. 1999; 116(4, suppl):A89. Abstract.
17. Quercia RA, Fan C, Liu X et al. Stability of omeprazole in an extemporaneously prepared oral liquid. Am J Health-Syst Pharm. 1997; 54:1833-6.
18. Chun AHC, Eason CJ, Shi HH et al. Lansoprazole: an alternative method of administration of a capsule dosage formulation. Clin Ther. 1995; 17:441-7.
19. Chun AHC, Shi HH, Achari R et al. Lansoprazole: administration of the contents of a capsule dosage formulation through a nasogastric tube. Clin Ther. 1996; 18:833-42.